



2021-2022

AHMEDABAD OBSTETRICS AND GYNAECOLOGICAL SOCIETY

AOGS TIMES

OCTOBER 2021

VOLUME 7

THEME : IMPLEMENTATION OF EVIDENCE BASED CLINICAL CARE

MOTTO : SWEAT, SMILE & REPEAT

President

Dr. Jignesh Deliwala

+91 98250 44819

jadeliwala@yahoo.co.in

Hon. Secretary

Dr. Munjal Pandya

+91 97129 11784

munjal171184@yahoo.co.in

Happy
Navratri



Immediate Past President FOGSI : Dr. Alpesh Gandhi

President - Elect
Dr. Kamini Patel

+91 94260 48748

drkaminipatel@hotmail.com

Vice President
Dr. Mukesh Savaliya

+91 98245 41292

mvsavaliya68@gmail.com

Hon. Treasurer
Dr. Snehal Kale

+91 98240 95580

kalesnehal@yahoo.com

Hon. Jt. Secretary
Dr. Nita Thakre

+91 98250 42238

drthakre@gmail.com

Clinical Secretary
Dr. Shashwat Jani

+91 99099 44160

drshashwatjani@gmail.com

Managing Committee Members

Dr. Akshay Shah | Dr. Anjana Chauhan | Dr. Bina Patel | Dr. Darshini Shah
Dr. Divyesh Panchal | Dr. Hetal Patolia | Dr. Jayesh Patel | Dr. Mehul Sukhadiya | Dr. Parth Shah | Dr. Praful Panagar

Ex-Officio

Dr. Rajal Thaker | Dr. Sunil Shah

Co-Opt. Members

Dr. Dipesh Dholakiya | Dr. Hemant Bhatt

Special Invitee

Dr. Arati Gupte Shah | Dr. Devindraben Shah | Dr. Parul Kotdawala
Dr. Sanjay Shah | Dr. Sujal Munshi | Dr. Tushar Shah | Dr. Yamini Trivedi

Chief Editor : Dr. Munjal Pandya | Co-Editors: Dr. Arati Gupte Shah | Dr. Hetal Patolia

2nd Floor, Ahmedabad Medical Association Building, Ashram Road, Ahmedabad - 380009.
Phone : 079 - 26586426 | E-mail : office@ahmedabadobgyn.org | www.ahmedabadobgyn.org



Creating miracles

with 3D Laparoscopy for fertility

Enhancing surgeries

Aesculap's Einstein Vision 3.0
3D Laparoscopy system



 **sunflower**
Women's Hospital
Ahmedabad

Available Services:

- Female / Male Infertility Clinic
- High-End Sonography, Colour Doppler and 4-D Sonography Centre
- Advanced Gynaec Endoscopy Centre
- IUI - IVF - ICSI - PGS - PGD
- Donor Sperm - Donor Egg - Donor Embryo
- PESA / TESA / Micro TESE for Azoospermia
- NABL Certified Endopath Laboratory
- Egg Freezing



We are the reason behind

14000+
SUCCESSFUL IVF PREGNANCIES

 **sunflower**
Women's Hospital
Ahmedabad

Sunflower Women's Hospital

Memnagar, Ahmedabad - 380052. Gujarat

Tel.: 079-2741 0080 / 90 +91-96876 07355

Email: drrgpatel@sunflowerhospital.in

Website: www.sunflowerhospital.in





Dr. Jignesh Deliwala
President

TEAM AOGS MESSAGE



Dr. Munjal Pandya
Hon. Secretary

નવરાત્રી- આસો મહિનામાં ઉજવાતો, માતાજીનો મહિષાસુર પરનો વિજય;
અનિષ્ટ પર સારાની જીત.
નવ દિવસ અને નવ રાત્રિ કરવામાં આવતી માતાજીના વિવિધ રૂપોની આરાધના.

દશેરા - સીતાજી અને શ્રીરામના ધર્મ અને ધીરજ; લક્ષ્મણ, હનુમાન અને અન્ય સર્વેના કર્તવ્યપાલનનો
અસુર સમ્રાટ રાવણના અભિમાન અને અધર્મ પર વિજય!

We had restrictions for celebrating Navaraatri, but we hope that everyone could celebrate it joyfully following proper guidelines and could instill happiness and new enthusiasm with life coming back on track...

Such festivities do instill 'જોશ' in monotonous routines. We welcome Diwali next month with all new hope, wishing everyone life full of health and happiness in forthcoming times!

We have prestigious Presidential Conference by Dr. Alpesh Gandhi with the whole team of ICCOB, in December 2021. The details are attached in one of the pages inside. Please do register at the earliest and get benefitted from Global as well as National and Our Own Society's Stalwarts!



We wish you all 'શુભ દીપાવલી' and 'નૂતન વર્ષાભિનંદન' in advance,
from Team AOGS!
May we all and our families,
Prosper and Progress with Health, Wealth and Happiness!

Dr. Jignesh Deliwala
President

Dr. Munjal Pandya
Hon. Secretary

PAST PROGRAMME

AOGS & FOGSI Medical Disorders in Pregnancy Committee

Invite you to a Scientific Program

At : Radisson Blu Hotel, Near Panchwati Cross, Ambawadi, Ahmedabad
Date : 10th October, 2021 | Time : 9.00 AM Onwards



CHAIRPERSON



Dr. Jayesh Dholakia
President, AOGS



Dr. Manoj J. Pandya
Hon. Secretary, AOGS

CO-CHAIRPERSON



Dr. Jayesh Patel



Dr. Anand K. Chavan
Chairman



Dr. S. Shrinivasan
President, FOGSI



Dr. Shikha Parthi
VP Exchange



Dr. Madhuri Patel
Secretary General

PROGRAM FLOW

Topic 1 : Obstetric Analgesia & Anaesthesia
Speaker : Dr. Dhresh Shah

Topic 2 : Obesity and Pregnancy
Speaker : Dr. Manoj Pandya

Topic 3 : PPRDM
Speaker : Dr. Kamal Chavan

Pain Disorder: Initiation of Labor

Moderator: Dr. Harsh Desai

Panelists:








Breakfast from 9:00 AM Onwards | CME Award to be Followed by Lunch

Substantial Partner  **Makers of**  

2 ICOG CREDIT POINTS GRANTED

ISOPARB PRAYAGRAJ

present:

Scientific Sangam-10

in association with
Ahmedabad & Baroda Obs. & Gynae Societies



ICOG
CME

20th Anniversary

4:30 - 6:30



Dr. Manoj Pandya
President, AOGS



Dr. Kamal Chavan
President, FOGSI



Dr. Gauri Patel
President, Baroda Obs. & Gynae Society

Scientific Session 1 Managing delivery in placenta previa (Moderator: Manoj Pandya)





Scientific Session 2 Managing pregnancy in elderly women





Scientific Session 3 Sarcopenia - An emerging menace





Scientific Session 4 Examination of New Born





Zydus

https://www.zydus.com.in/website/m/india/WH_C999995510/india2021

Phone: F. 834 1130 9392 | Fax: 834 1130 9392









PAST PROGRAMME



ART Fertility Clinics in association with Ahmedabad Obstetrics and Gynaecological Society (AOGS) cordially invites you to an inaugural CME on Fertility Management



Chairpersons:

Dr. Kamini Patel

Dr. Nisarg Dharaiya

Dr. Azadeh Patel



TOPIC	SPEAKER	TIME
Evidence Based Psychosocial Care in Medically Assisted Reproduction (MAR)	Dr. Gurpreet Singh Kalra Medical Director ART Fertility Clinics, India	8:00 pm - 8:20 pm
New Developments in Induction of Ovulation	Prof. Dr. Human Fatemi Group Medical Director ART Fertility Clinics	8:20 pm – 8:50 pm
PGT-A: Overcoming the Challenges	Mr. Ibrahim ElKhatib Chief Embryologist ART Fertility Clinics	8:50 pm – 9:10 pm
Interactive Session		9:10 pm – 9:25 pm
Dinner		9:25 pm Onwards

Venue: Radisson Blu Hotel
Near Panchvati Cross Road, Off C.G. Road, Ambawadi, Ahmedabad-380006

www.artfertilityclinics.com

FINAL RESULTS IN IMA NATIONAL OLYMPICS HELD AT NASHIK MAHARASHTRA

CONGRATULATIONS
Dr. Falgoon S. Parikh



WON TOTAL 12 SILVER MEDALS

at the end of the Mega Sports Event held on in November end 21
The Highest individual medal winner from Gujarat and also Nationally.
(Includes the whole event)

RESULTS

Freestyle	Breaststroke	Backstroke	Butterfly
50 , 100 , 200 metres	50 100 200 metres	50 100 200 metres	50 100 200

SILVER MEDALS IN ALL 12 EVENTS

State Champion in Khel mahakumbh Gujarat
National Bronze Medalist in open MASTERS SWIMMING COMPETITION 2018 at vishakhpatnam

Ahmedabad Medical Association
Installation Ceremony - Year 2021 - 2022

President
Dr. Dilip Gadhavi



Ahmedabad Medical Association
Installation Ceremony - Year 2021 - 2022

President - Ladies Club
Dr. Praful Panagar



PAST PROGRAMME



AHMEDABAD OBSTETRICS & GYNAECOLOGICAL SOCIETY

Date : 31st October, 2021 - Sunday

Time : 10.00 am to 1.00 pm

Venue : Hotel Radisson Blu, Panchvati, Ahmedabad.



DR. JIGNESH DELIWALA
PRESIDENT, AOGS



DR. MUNJAL PANDYA
HON. SECRETARY, AOGS

Co-Ordinator :



DR. JAYESH PATEL


Subject Experts :



DR. YAMINI TRIVEDI



DR. MUKESH SAVALIYA



Speaker

**October :
'Down's Syndrome Awareness Month'**

DR. DARSHANA THAKKAR



Speaker

Obstetric analgesia & anaesthesia

DR. BHADRESH SHAH



Speaker

**Medico legal aspects in
obstetrics haemorrhage**

DR. M. C. PATEL



Speaker

Carbetocin

DR. JAYESH PATEL

Moderator :



DR. ALPESH GANDHI

Panelists :



Dr. Ajit Rawal



Dr. Sapna Shah



Dr. Dipesh Dholakiya



Dr. Hetal Patoliya



Dr. Mahendra Soni



Dr. Yamini Trivedi



Dr. Mukesh Savaliya



Obesity and Pregnancy



Dr. Janki Pandya

Assistant Professor, AMC MET Medical College



Dr. Munjal Pandya

Assistant Professor, AMC MET Medical College

- WHO declared obesity as a Global epidemic (2000)
- NFHS-4 (2015–16): The national prevalence of obesity in pregnancy (12%) and in the postpartum period (13%)
- BMI: According to WHO & NICE; classification is based largely on association between BMI and mortality

Table 1 Classification of weight status according to BMI^{1,2}

BMI (kg/m ²)	Classification
< 18.5	Underweight
18.5–24.9	Normal/healthy ³
25.0–29.9	Overweight
30.0–34.9	Obese I
35.0–39.9	Obese II
>40	Obese III

BMI = body mass index

Limitations of BMI:

- Inconclusive about distribution of adipose tissue v/s absolute amount; Inconclusive about Abdominal obesity v/s Accumulation of fat around the hips and thighs; unable to distinguish between muscle and fat mass; Across different populations, a given BMI may not correspond to the same degree of ‘fatness’
- Waist circumference : Better measure of visceral adiposity and its associated risk (Sattar N, 2001)

Ante-natal

- Nutritional Deficiency
- 40% deficient in Iron, 24% deficient in Folic Acid, 4% deficient in Vit B12
- Folic Acid, Calcium and Iron supplements
- Tendency towards straying away from fortified cereals, fruits and vegetables; and eating more of processed foods, high in calories, but low in nutritional value.
- Ideal diet: Healthy mix of fruits and vegetables, lean proteins, good quality carbohydrates
- **Weight gain during pregnancy:**
- GWG (Gestational Weight Gain): composite of products of conception, plasma volume expansion, extracellular fluid, maternal fat deposition, and imprecise estimate of increasing maternal (or fetal) adiposity.
- Excessive wt gain: very high risk of complications, including indicated preterm birth, CS, failed labour induction, LGA infants, infants with hypoglycemia.

IOM (Institute of Medicine)		Optimal wt gain (Cedergren MI, 2007)	
Underwt (BMI<18.5)	12.5-18 kg	Underwt	4-10 kg
Healthy (BMI 18.5-24.9)	11.5-16 kg	Normal wt	2-10 kg
Overwt (BMI 25-29.9)	7-11.5 kg	Overwt	<9 kg
Obese (BMI >30)	5-9 kg	Obese	<6 kg

- Obese women with less wt gain: reduced risk of pre-eclampsia, CS, instrumental delivery, LGA babies.
- Kiel DW, 2007: 4 outcomes were studied for pregnancy wt gain and obesity class: pre-eclampsia, CS, LGA and SGA)- 1st 3 outcomes decreased with reduced wt gain, but SGA increased. Conclusion was drawn that overall minimal risk for mother and baby should be taken at point of equal risk of LGA and SGA corresponding with wt gain of 4.5-9 kg for class 1 (BMI 30-34.9), 0-4 kg for class 2 (BMI 35-39.9) and class 3 (BMI ≥40)

Challenges with diagnostic tests:

- Excess body fat can make it challenging for USG examination. TVS can be considered in whom transabdominal USG can't conclude NT. Increased echogenicity of adipose tissue and increased absorption of ultrasonic sound beam by abdominal fat

- FHS: difficult to be heard by Auscultation
- BMI > 35 kg/m², are likely to have inaccurate SFH and should be referred for serial assessment of fetal size using USG
- Appropriate Sphygmomanometer cuff size, with its documentation

Maternal Complications associated with Obesity:

- **HDP, Pre-eclampsia:** Direct correlation between maternal BMI and risk of preeclampsia. (*O'Brien TE, 2003*). Pre-pregnancy BMI >35 increased the risk of preeclampsia four-fold compared with women with a pre-pregnancy BMI of 19–27.
- **Waist circumference:** A non-pregnant waist circumference 80 cm has been associated with an OR for pregnancy-induced hypertension of 1.8 and for preeclampsia of 2.7 in a cohort of over 1000 unselected pregnancies. (*Sattar N, 2001*)
- **GDM:** Retrospective UK study of 287,213 pregnancies between 1989 and 1997: women with a BMI >30 were more likely to develop gestational diabetes than women with a BMI of 20.0–24.9 (*Sebire NJ, 2001*). (GDM) increases the long-term risk of developing type 2 diabetes. (*Lauenborg J, 2004*)
- **Obstructive sleep apnea:** Sleep apnea can cause fatigue, increases risk of HTN, pre-eclampsia, heart and lung problems.
- **VTE:** 57% of Maternal Deaths from VTE in the UK were obese. Denmark: Retrospective case-control study: A significant association between VTE and obesity (*Larsen TB, 2007*). Associated problems of reduced mobility, co-morbid conditions that predispose to thrombosis, such as preeclampsia, and an increased frequency of operative delivery, higher levels of coagulation factors
- **Preterm birth:**
- Obesity is associated with lesser incidence of spontaneous preterm birth, but more of medically indicated induced preterm birth, as compared to non-obese counterparts.
- **Respiratory System:**
- Respiratory disease (asthma and obstructive sleep apnea) increases risk of non pulmonary pregnancy complications, such as CS and pre-eclampsia. Upto 30% experience an exacerbation of their asthma during pregnancy (1.5 times more than non obese). Wt loss b/w pregnancies reduces risk of SB, hypertensive complications and fetal macrosomia. Wt loss increases chances of successful VBAC.

Fetal complications during pregnancy:

- Higher incidence of first trimester miscarriage (OR 1.2) (*Lashen H, 2004*)
- **Birth defects:** increased risk of heart defects and NTD. 3-fold risk of spina bifida, omphalocele and heart defects in babies of obese mothers. Confirmed association between maternal obesity and spina bifida, heart defects, anorectal atresia, hypospadias, limb reduction defects, diaphragmatic hernia, omphalocele. (*Watkins ML, 2003; Cedergren MI, 2003; Waller DK, 2007*)
- **Macrosomia:** high risk of birth injuries; high chances of CS. Nearly a fifth of women with a BMI ≥30 had fetal macrosomia; independent of whether the mother also had pre-existing or gestational diabetes. (*Jolly MC, 2003*). Macrosomia is a risk factor for operative delivery, a low Apgar score at one minute and a low umbilical arterial pH level, as well as shoulder dystocia and significant injuries to the baby, including fractures and nerve palsies.
- **Preterm birth:** Medically indicated preterm birth.
- **Stillbirth:** Higher BMI, greater risk of SB. Women with a BMI >30 had a stillbirth rate of 6.9/ 1000 total births compared with 4/1000 total births in women with a BMI of 20–25 (adjusted OR 1.40)
- **Cerebral Palsy:** The risk of developing cerebral palsy increases with increasing BMI, risk being 22%, 28%, 54%, 202% for Overweight, Obesity class 1, Obesity class 2, Obesity class 3 respectively.
- **Neonatal Death**

Intra-partum:

- Difficulties with venous access
- *Vahratian A, 2004:* Women with a BMI ≥30 were more likely than women with a BMI ≤26 to have their **labour induced** and to receive oxytocin. Labour progression from four to 10 cm was slower in obese women (7.9 versus 6.2 median hours). These data suggest that obesity is associated with inefficient uterine activity in labour.
- **Primary emergency caesarean section rates** were higher for obese women compared with women with a healthy BMI (27% versus 19%, P, 0.04), with the majority of the deliveries occurring during the first stage of labour for failure to progress in labour and fetal distress
- **Anesthesia:** Increased requirements, higher risk of anaesthesia-related morbidity, higher epidural failure rate (*Dresner M, 2006*). Increased risk of aspiration under general anaesthesia, Difficult endotracheal intubation, Difficulty in achieving regional analgesia/anaesthesia, Postoperative hypoxaemia and atelectasis. Co-morbidities

such as hypertension, ischaemic heart disease and heart failure, adding to the risks associated with anaesthesia

- **C.S.:** Preoperative skin cleansing before CS. Vaginal cleansing using povidone-iodine/Chlorhexidine gluconate before CS in laboring pts and those with ruptured membranes may be considered. (*ACOG, 2018*). Surgical access to uterus: Transverse incision was found to be better than vertical incision (*RCOG GTG, 2018*). Class 3 obesity is associated with increased rates of uterine rupture during trial of labour and neonatal injury. Emergency CS is associated with increased risk of serious maternal morbidity because of anesthetic and operative difficulties
- Suturing of subcutaneous fat: More than 2 cm depth of subcutaneous fat layer will require suturing of the layer. Negative suction drain in that layer has not found to be of additional advantage.

Post Partum:

- **Hemorrhage and Infections:** PPH, Genital tract infection, UTI, wound infection.
- Increased risk of VTE after both CS and ND. Postpartum infection with obesity may increase chances of VTE.
- **Breastfeeding:** BF rates are poor among obese (*Amir LH, 2007*). Possible reasons: difficulty with correct positioning of baby, psychological issues, or endocrine issues such as prolactin response to suckling. (*Rasmussen KM, 2004*).
- Challenges for BF: takes longer for the milk to come in, lower production (breast size has nothing to do with amount of milk produced). Indicated preterm and admission in NICU means prolonged separation of mother from baby. Plus higher rates of maternal complications along with CS reduce the rate further.
- BMI > 40 kg/m² is a risk factor for developing pressure sores; immobility being one more risk factor
- **Mental health problems:** high prevalence of depression symptoms. High antenatal anxiety, postpartum anxiety, eating disorders, antenatal serious mental illness.
- **Long term implications in childhood:** Intra-uterine exposure to obesity is associated with increased risk of developing obesity and metabolic disorders in childhood. (*Barker hypothesis, 1990*)
- **HAPO Study:** Amongst obese women: Raised maternal blood glucose, Raised tryglyceride and fatty acids, and fetal insulin concentrations, contributing to fat accretion in offspring. Maternal and cord blood leptin conc is elevated, with evidence of low grade inflammatory state in mother with high levels of CRP and IL 6; linked to insulin resistance.

Management:

- **Folate** Supplementation: 400 microgram daily
- **Wt loss:** loss of 4.5 kg b/w 2 pregnancies reduced risk of developing GDM by upto 40%. (*Glazer NL, 2004*)
- 10% wt loss over 6 months is ideal, safe and possible to sustain in long term.
- Wt loss during first trimester may increase NTD; but prior to pregnancy does not appear to carry this risk. (*Carmichael SL, 2003*)
- **Following Bariatric Surgery:** Maternal and perinatal complications were less
- Dumping syndrome: To avoid same, OGTT isn't recommended for women who had bariatric surgery; instead, Home based glucose monitoring for at least 1 wk is advisable. (*Ukleja A. 2005*)
- RCOG GTG, 2018 & ACOG: Min waiting period of 12-18 months after bariatric surgery is recommended before attempting pregnancy
- RCOG GTG (2018): women with more than one moderate risk factor (BMI of 35 kg/m² or greater, first pregnancy, maternal age of more than 40 years, F/H of pre-eclampsia and multiple pregnancy) may benefit from taking 150 mg **Aspirin** daily from 12 wks of gestation until birth of baby.
- **Regular Moderate intensity physical activity:** RCOG (2006) & Cochrane review suggested regular aerobic exercise during pregnancy improved maternal fitness, beneficial effects of fetal growth. (*Kramer M, 2008*)
- Anti-obesity or wt loss drugs are NOT recommended for use in pregnancy: Orlistat- No major malformation risk. Phentermine/Topiramate- Topiramate during pregnancy- oral clefts; both are excreted in breast milk, and carries unknown risks to infant. (*RCOG GTG 2018*)
- Metformin: for overwt/obese pts without DM; addition of metformin to diet and lifestyle changes, starting at 10-20 wks DID NOT have improved pregnancy/birth outcome. (*Dodd JMet et al. 2019*)
- Type 2 DM steep increase within first 5 years

Future Prospects:

- Prospective RCT are needed in obese pregnant women to assess
- Effects of diet, physical activity, lifestyle changes on maternal, fetal and neonatal outcomes.
- ? Optimal wt gain is needed
- ? Optimal methods of assessing body fat in women
- ? Optimal gestation of screening obese women for GDM and whether early detection and management improves outcomes

Antihypertensive Treatment- Newer Insights



Dr. Sanjay Gupte



Dr. Arati Gupte Shah

The treatment of pregnancy hypertension has always been controversial for various reasons.

First is the classification as it stands. Gestational Hypertension, Chronic Hypertension, Preeclampsia and Superimposed Preeclampsia, though now defined categorically, still lacks specificity.

Traditionally the level of 140/90 mm of Hg is considered the minimum level for diagnosis. From 140 to 159 mm of Hg systolic and 90 to 109 mm of Hg diastolic is considered mild hypertension. Some guidelines divide this between mild and moderate.

The only non controversial figure is 160/110 mm of Hg which is taken as severe hypertension.

Second point of difference is: traditionally in contrast to hypertension guidelines in adults, which emphasizes the importance of systolic BP, much of the obstetric literature focuses on diastolic rather than systolic BP; in part, because of the lack of clinical trials to support one approach versus another.

During pregnancy, antihypertensive agents are mainly used to prevent and treat severe hypertension; to prolong pregnancy for as long as safely possible, to maximize the gestational age of the fetus; and to minimize fetal exposure to medications. So the challenge is in deciding when to use antihypertensive medications and what level of BP to target.

The choice of antihypertensive agents is less complex, because only a small proportion of currently available drugs have been adequately evaluated in pregnant women, and many others are contraindicated.

Treatment of Severe Hypertension

There is consensus that severe hypertension in pregnancy, defined as 160/110 mm Hg, requires treatment, because these women are at an increased risk of intracerebral hemorrhage, and that, treatment decreases the risk of maternal death.^{1,2}

In treating severe hypertension, it is important to avoid hypotension, because the degree to which placental blood flow is autoregulated is not established, and aggressive lowering may cause fetal distress.

Protocol for management of severe hypertension

BP more than 160/110 with emergent presentation

IV Labetalol 5 mg. 1st dose, double every 15mins. To Max.300mg.

Nifedipine 10mg. Oral every 20mins. Max. 90mg.

IV Hydralazine 10mg. IV every /15 mins. Max. 300mg.

Nitroprusside 0.25micro g./kg/min. Max. 10micro g./kg/min.

Use of Nicardipine

Nicardipine acts more selectively on the blood vessels than on the myocardium, with less reflex tachycardia. In a multiple-center placebo-controlled study, intravenous nicardipine was shown to be both effective and safe in patients with severe hypertension.

Onset of action is in 10 mins and results in adequate reduction of BP within 20 mins (duration of action 4–6 hrs). The most common adverse reaction was headache.

Comparison of labetalol and nicardipine in severe hypertension

Sixty consecutive pregnant women admitted beyond the 24th wk of pregnancy with severe hypertension³. Patients were randomly assigned to receive intravenously for 1 h either labetalol (n=30) or nicardipine (n=30). Treatment was titrated to achieve a 20% lowering of blood pressure (BP).

Labetalol and nicardipine achieved the 20% lowering in BP in the same proportion (63% and 70% success rates, respectively). Overall nicardipine caused a significantly greater decrease in systolic and diastolic BP. No patient had any episode of hypotension.

The length of time to achieve the BP goal was also similar (12 vs. 11 min, respectively). Both drugs were well tolerated except for a moderate tachycardia observed with the use of nicardipine.

Treatment of mild to moderate hypertension.

This is still a controversial issue for many.

In favour of treatment is the fact that blood pressure may be extremely labile in preeclampsia and treatment at lower blood pressure levels will prevent or attenuate acute and severe rises in blood pressure. In addition, it is possible that pharmacologic arteriolar vasodilation may help improve organ perfusion.

Arguments against treatment include that there is little risk to the mother in having relatively mild hypertension for a short time (usually only a few days or at the most weeks), that fetal perfusion is dependent upon adequate maternal blood pressure and that, lowering blood pressure suppresses an important sign of the severity or progression of preeclampsia.

Principles for Treatment of Mild-to-Moderate Hypertension in Pregnancy

The benefits of antihypertensive therapy for mild-to moderately elevated BP in pregnancy (160/110 mm Hg), either chronic or pregnancy induced, have not been proved in clinical trials.

Recent reviews, including a Cochrane meta-analysis in 2007⁴, concluded that there are insufficient data to determine the benefits and risks of antihypertensive therapy for mild-to-moderate hypertension (defined as 140 to 169 mm Hg systolic BP and 90 to 109 mm Hg diastolic BP).

A retrospective review of 28 patients who suffered stroke in the setting of preeclampsia demonstrated that the cause of stroke was usually arterial hemorrhage, that the average BP before stroke was 159 to 198 mm Hg systolic and 81 to 133 mm Hg diastolic, and that 54% of women died.⁵

Of note, systolic hypertension (155 to 160 mm Hg) was more prevalent than diastolic hypertension (most women did not reach a diastolic BP of 110 mm Hg) in women who suffered strokes. This case series underscores the need for clinical trials and evidence-based guidelines for antihypertensive treatment in pregnant women.

A 2014 Cochrane systematic review of 49 trials (4,723 women) concluded that treatment of mild-to moderate hypertension reduced the risk of developing severe hypertension but had no effect on the incidence of preeclampsia, preterm birth, fetal death, fetal growth restriction, or any other measured outcome⁶.

The theoretical concern of fetal harm (primarily growth restriction) resulting from possible impairment of the uteroplacental blood flow was not found in this systematic review.

The CHIPS trial⁷ (Control of Hypertension in Pregnancy Study) has provided evidence that antihypertensive treatment of nonsevere hypertension in pregnancy is of benefit to the mother, without associated perinatal risk.

This was an open international multicenter trial with 937 women with nonsevere, non proteinuric pre-existing or gestational hypertension. The patients were randomized into 2 groups- tight control group and less tight control group. Analysis showed that within the same population, less tight control is associated with more severe hypertension, that severe hypertension is a risk marker for adverse maternal and perinatal outcomes, and that the risks associated with severe hypertension are over and above those associated with the co-occurrence of preeclampsia.

CHIPS data also indicates that severe hypertension is an outcome worthy of avoidance to minimize maternal and perinatal risk. As such, we should move from detection and prompt treatment of severe hypertension to prevention.

This can be achieved with antihypertensive therapy to normalize maternal BP, as practiced in the tight BP control arm of the CHIPS trial, aiming for a modest dBp of 85 mm Hg. Future work should focus on whether one antihypertensive agent offers advantages over another.

Which Drug should be used?The Indian context

The choices that we have today :

Alpha- methyl dopa : time tested

Nifedepine : fast and effective

Labetolol : oral as well as injectable

New addition -- Amlodipine

Amlodipine is among the most widely prescribed antihypertensive medications for nonpregnant individuals; however, initially, only limited data (<50 cases) regarding safety in pregnancy were available.^{8,9}Mito and colleagues recently (2019) reported important new information about amlodipine exposure in the first trimester of pregnancy.¹⁰They concluded that, based on this admittedly small sample of 231 patients, amlodipine exposure in early pregnancy does not appear to be associated with an increased rate of fetal malformations compared with other antihypertensive medications or maternal hypertension without treatment.

Would there be any reasons to preferentially use amlodipine rather than Nifedepine SR in pregnancy, provided sufficient safety data were available?

Both are dihydropyridine CCBs, and lower BP similarly by preventing the entry of calcium through L-type calcium channels in the vasculature.^{11,12} The half-lives of the various dihydropyridines differ, which may affect BP control over a 24-hr period.

Amlodipine is one of the longest acting dihydropyridine CCBs. Amlodipine is tolerated well. It can be given in single dose. No adverse side effects are noted like Sudden Hypotension, Tachycardia, FGR.

Nifedipine SR is designed to provide BP control at a constant rate over 24 hours and has a shorter half-life than amlodipine (≥ 44 hours),¹¹ but in most patients it provides adequate BP control over a 24-hour period, provided the dose is adjusted appropriately.

Conclusions

The development of severe hypertension raises concern about elevated stroke risk, but the CHIPS data demonstrate that the risk of other adverse perinatal and maternal outcomes, including serious maternal complications, is also increased, independently of the co-occurrence of preeclampsia.

Hence it is wise to start controlling mild hypertension to prevent severe hypertension. So tight control seems to be the way forward.

References:

1. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. *Am J Obstet Gynecol.* 2000;183:S1–S22.
2. Rey E, et al Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy. *CMAJ.* 1997; 157:1245–1254
3. Elatrous F et al. Short-term treatment of severe hypertension of pregnancy: prospective comparison of nifedipine and labetalol. *Intensive Care Med.* 2002 Sep;28(9):1281-6. doi: 10.1007/s00134-002-1406-3. Epub 2002 Jul 26. PMID: 12209278.
4. Abalos E, Duley L, Steyn D, Henderson-Smart D. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. *Cochrane Database Syst Rev.* 2007;CD002252.
5. Martin JN Jr, Thigpen BD, Moore RC, Rose CH, Cushman J, May W. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. *Obstet Gynecol.* 2005;105: 246–254
6. Abalos E, Duley L, Steyn DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. *Cochrane Database of Systematic Reviews* 2014, Issue 2. Art. No.: CD002252. (Systematic Review and Meta-Analysis)
7. Magee LA, et al. Less-tight versus tight control of hypertension in pregnancy. *N Engl J Med.* 2015;372:407–417. doi: 10.1056/NEJMoal404595
8. Weber-Schoendorfer C et al The safety of calcium channel blockers during pregnancy: a prospective, multicenter, observational study. *Reprod Toxicol.* 2008;26:24–30
9. AhnHK, et al Exposure to amlodipine in the first trimester of pregnancy and during breastfeeding. *Hypertens Pregnancy.* 2007;26:179–187
10. Mito A et al. Safety of amlodipine in early pregnancy. *J Am Heart Assoc.* 2019;8:e012093. DOI: 10.1161/JAHA.119.012093
11. Elliott WJ, Ram CV. Calcium channel blockers. *J Clin Hypertens (Greenwich).* 2011;13:687–689.
12. Ghamami N, Chiang SH, Dormuth C, Wright JM. Time course for blood pressure lowering of dihydropyridine calcium channel blockers. *Cochrane Database Syst Rev.* 2014;Cd010052






Shukan Hospital
IVF CENTRE
LAPROSCOPY 4D SONOGRAPHY MATERNITY





High Result with less expense

15 years of experience

Highly skilled clinical team

1000+ Successful IVF Pregnancy

3000+ Laparoscopy & Hysteroscopy Surgery

Available Facility

- Male & Female Infertility Clinic
- IUI - IVF - ICSI
- Donor Egg
- Donor Embryo
- Surrogate Mother
- PESA/TESE/Micro TESE for Male
- Advance Gynec Endoscopy Center
- 3D-4D Sonography & Colour Doppler
- High Risk Pregnancy Unit
- Advance Fetal Medicine Centre

Dr. PRAKASH PATEL
IVF & Infertility Specialist
Dipl. in Adv. Laparoscopy (France)
Diploma in Sonography (Croatia)



Dr. AJAY PRAJAPATI
MS. Gynec (Infertility & Foetal Medicine Specialist)



Dr. HEMAXI CHANGELA
Gynecologist (Fetal Medicine Expert)

SHUKAN IVF CENTRE & WOMEN'S HOSPITAL : 246, Shukan Mall, Science City Road, Sola, Ahmedabad. Ph. 079 27712244, M. 70419 40220 | www.shukanhospital.com | shukanhospital@gmail.com



NOW, HIGHEST STANDARD OF QUALITY & EXCELLENCE IN IVF TREATMENTS AT WINGS IVF



WINGS IVF BECOMES ONLY
THE SECOND HOSPITAL
IN THE CATEGORY TO HAVE

FULL NABH ACCREDITATION*

SCOPE OF SERVICES

INFERTILITY & IVF TREATMENTS ◀
FOETAL MEDICINE ◀

ADVANCED GYNAEC ◀
ENDOSCOPY DEPARTMENT
GYNAEC ONCO SURGERIES •
GRADE 3 & 4 ENDOMETRIOSIS •

Spread across 25,000 sq. ft space of ultra-modern infrastructure,
WINGS IVF holds more than 17 years of experience
with happiness of providing 20,000 live births through IVF



For more Information Contact :
+91 7878 777 222, 98250 50565
Or log on : www.wingshospitals.com

WINGS IVF Women's Hospital

17, Sunrise Park, Himalaya Mall-Vastrapur Lake Road,
Bodakdev, Ahmedabad.

AHMEDABAD | SURAT | RAJKOT | UDAIPUR | KENYA

WHEN YOU ARE AT WINGS, YOU ARE IN SAFE HANDS.



MOTHERHOOD IVF CENTRE

IVF | IUI | SURROGACY

"Together We Make Family"

A Subsidiary Branch Of Motherhood Women's & Child Care Hospital Pvt Ltd

- Advance Hi-tech IVF & Infertility Centre
- More than 20 years Experienced IVF Team
- Successfully done 10,000 Plus IVF & 6000 IUI till date

We are a prestigious and trusted IVF (Test Tube baby) Treatment Center having world-class technology and skilled doctors to facilitate infertility treatments. there are only a few hospitals that are reliable and are equipped with technology. Motherhood is one of the best hospitals in Ahmedabad to avail services for infertility treatments. To achieve a higher success rate. Motherhood Hospital is equipped with test tube baby facilities and ultramodern technology. We offer affordable treatments with quality and superior equipment so that you can avail of our services swiftly. The Motherhood team of Doctors and staff work together to bring you the best arrangements for Egg Donor, Sperm Donor and Surrogacy. We are happy to be a part of the journey of several couples who became parents after our IVF treatments.

- ICSI (Intra cytoplasmic Sperm Injection)
- IMCI (Intra Cytoplasmic Morphological Sperm injection)
- TESA (Testicular sperm Aspiration)
- MESA (Microsurgical Epididymal Sperm Aspiration)
- Egg Donation
- Surrogate Mother
- Semen Donation
- Embryo Freezing
- Oocyte Freezing
- Thaw Cycle

IVF Lab.



PGT



Ovum Pick up Room



Our Doctors Team



Dr. Anand B. Patel
M.D., D.G.O.
Diploma in Gynec Endoscopy, Diploma in Gynec Endoscopy,
(C.I.C.E. - France),
Diploma in Sonography



Dr. Rajesh Punjabi
M.D., Gynec
(C.I.C.E. - France)



Dr. Shital Punjabi
M.D., D.G.O.
(Gold Medalist)
Art Specialist (USA)



Dr. Prerana Shah
M.B.B.S., D.G.O
Gynecologist &
Infertility Specialist



Yuvrajsinh Thakore
ESHRE Certified Embryologist
Fellowship in Embryology
UMCG (Netherlands)

SF - 211 Shivalik Square, 132 Ft. Ring Road, Opp GSRTC Ranip Bus Stand, Nr. Adani CNG Pump, Navavadaj, Ahmedabad 380013



97246 64433 | 97246 64488



www.motherhoodhospital.com
motherhoodivfcentre@gmail.com





www.snehhospitals.com
7048331000

We at sneh hospital are extremely excited to announce the installation of

"MATCH WITNESS SYSTEM"

Not Only The First Centre in Gujarat but Entire Western India for having this technology.

- It Eradicates mismatch / mix up of biological samples by which we can reassure the couples of a smooth, stress free IVF process, without any fear of a genetic mix up, hence providing psychological relief and a wonderful pregnancy.
- It's World's 1st all sided sensory mechanism (even useful in timeless Culture dishes)



Facilities : IVF- ICSI- BLASTOCYST CULTURE- LASER HATCHING-PGD PGS-MICRO TESA

SNEH

WOMEN'S HOSPITAL & IVF CENTRE

MANINAGAR, PRAHLADNAGAR, BODAKDEV, SURAT, BARODA

Dr. Nisrag Dharaiya | Dr. Ushma Patel | Dr. Shetal Deshmukh | Dr. Rushi Patel | Dr. Kushal Shah | Dr. Khushali Shah

WESTERN INDIA

1st

"MATCH WITNESS SYSTEM"



3rd Centre Across whole of india to have this technology



Patients entering the cycle will receive an RFID ID card with unique identity information



The blank chip is pre-pasted on the prepared vessels for further identification



In each workspace of the laboratory, data Analyzed Automatically



Tag Mismatch

System actively scans & confirms that there is no mismatch in the workspace, and automatically prompts the steps



Embryo Transfer Room

Before Embryo transfer, the system scans patient's ID card, witness the identification process



Respected Members,
Herewith we announce launch of our new website with all new updated features.

Web address : <https://www.ahmedabadobgyn.org/>

Advertisements for your hospitals/websites in AOGS website section can be given as follows :

For **6 Months**
Rs. 25,000/-

Please Contact AOGS Office for the same.

For **1 Year**
Rs. 50,000/-

Phone : 079 - 26586426

Dedicated to Care & Support All Phases of Womanhood

**Bioequivalent Dydrogesterone
Through Indigenous PB Technology**

Zuviston™

Micronized Dydrogesterone 10 mg Tablets

Trustworthy

-----> Purity, Hormonal Activity & Efficacy

**Novel Photon Bombardment Technology
Ensures Superimposable Structure
with Innovator**

1st Time Micronized Dydrogesterone

99.98% Pure Dydrogesterone

**Special Opadry Tablet Coating
Masks Bitter Taste**

A **Unique Probiotic Vaginal** Tablets

EvaNew Probiotic Vaginal Tablets

Atleast 1 Billion CFU of Mix Lactobacilli: *L. brevis* CD2,
L. salivarius FV2 & *L. plantarum* FV9 / Vaginal Tablet

Re-establishes and Maintains Healthy *Vaginal Flora*

**Carefully Selected Lactobacilli with
Proven Adherence to Vaginal Epithelium**

**Resolves Vaginal Infections &
Improves Reproductive Outcomes**

**Reduces Relaps in
Antibiotic Treated Patients**

Dosage: • 1 tablet intra-vaginal at bedtime for 8 days every month preferably from 8th day of menstrual cycle for 3 consecutive months

• Not to be given concomitantly with anti-infective pessaries

Storage: Maintain Cold Chain (Store between 2°C to 8°C. Do not freeze)

For the Management of Spontaneous Preterm Labour

Tosiban® 6.75MG 37.5MG

Atosiban Injection 6.75mg/0.9ml, 37.5mg/5ml

For IV Use Only

==== The **Best** & **Safest** Tocolytic Agent =====



Tosiban (Atosiban) in Spontaneous Preterm Labour

Tocolytic efficacy was sustained from
72 hrs (89.09%), to discharge ≤ 7 days (88.18%)

Upto **74 days** gained after tocolysis

Think IRON... Think

Feronia®-XT

Ferrous Ascorbate equivalent to elemental iron 100mg + Folic Acid 1.5mg/Tablet

Designed to Ensure Maximum Hb Rise

Provides **6:1** Optimal Ratio of
Ascorbic Acid to Iron



**Increases Iron Absorption
by 2-12 Folds¹**



Office No. 5119, 5th Floor, D-Wing, Oberoi Garden Estates,
Chandivali, Andheri (E), Mumbai 400 072.

For the use of Registered Medical Practitioner or Laboratory or Hospital only.



BSV

Birth right of every Rh-negative mother

To Prevent Sensitisation in Rh-negative mother

AntiDTM
Recombinant Anti-Rho (D) Immunoglobulin 300 mcg

Positive for Negative



Anti-D immunoglobulin Recommended by NHS UK

FOR ALL PREGNANT RhD NEGATIVE WOMEN WHO HAVEN'T BEEN SENSITISED TO THE RhD ANTIGEN¹






BSV
bringing life to life

For Prevention of Postpartum Hemorrhage due to Uterine Atony
Post Cesarean Section

CarbitexTM
Carbetocin 100 mcg/ml Injection

Prevents PPH Assures Motherhood





Dosage: 100 mcg IV to be given immediately after childbirth¹

1. WHO recommendations Uterotonics for the prevention of postpartum haemorrhage

Global Leaders in Reproductive Medicine Now in Ahmedabad

With science at the heart of everything we do, ART Fertility Clinics aim to help couples fulfill their dream of parenthood.

Five Pillars of ART Fertility Clinics:

- Clinical Excellence in Delivering the Highest Pregnancy Rates
- The Most Advanced Technology and Infrastructure
- Science and Innovation
- Compassionate Care, Patient Satisfaction and Safety
- Transparency and Highest Ethical Standards




ART Fertility Clinics: Sun Avenue One, 1st Floor, Above Banana Leaf Restaurant,
Manekbaug-Shyamal Road, Manekbaug Ambawadi, Ahmedabad-380015

iccob'21



An International Conference on

CRITICAL CARE in Obstetrics



Organized by
Ahmedabad Obstetrics and Gynaecological Society (AOGS)

WORKSHOPS

December 17, 2021, 09:00 to 17:00 Hrs

WORKSHOP#1
Critical Care In Obstetrics

WORKSHOP#2
Obstetrics Imaging

REGISTRATION DETAILS:

Category	Early Bird Before 30/10/21	Between 1/11/21 to 30/11/21	Spot Registration
FOGSI MEMBER	INR 7,670	INR 8,850	INR 10,030
NON FOGSI MEMBER	INR 8,850	INR 10,030	INR 11,210
ACCOMPANYING PERSON	INR 7,670	INR 8,850	INR 10,030
CONFERENCE+WORKSHOP	INR 9,440	INR 10,620	INR 11,800
FOREIGN DELEGATE	USD 200	-	-
PG STUDENT (physical presence)	INR 6,490	INR 7,080	INR 7,670

Registration Fees includes 18% GST

Paper Poster / abstract submission started
Submit your entry at iccob2021@gmail.com

*Paper and Poster Presentation will be online only by the registration at INR 500 (Only for PG students) & for practising gynecologist conference registration is mandatory.
*PG Student Paper poster presentation registration fees need to pay online only.

Conference Secretariat:

Ahmedabad Obstetrics and Gynaecological Society
2nd Floor, Ahmedabad Medical Association Building,
Opp. H. K. College, Ashram Road, Ahmedabad 380009, Gujarat.
Phone: 079-26586426 Mob.: +91 80006 22067

www.iccob.in

In association with



17 18 19

December '21
AHMEDABAD

Venue:
Shri Shakti Convention Center

ORGANIZING TEAM



Dr. Alpesh Gandhi
Org. Chairperson



Dr. Jignesh Deliwala
Org. Chairperson



Dr. Hemant Bhatt
Org. Secretary



Dr. Munjal Pandya
Org. Secretary



Dr. Sunil Shah
Org. Secretary

FOGSI TEAM



Dr. S. Shantha Kumari
President



Dr. Alpesh Gandhi
Immediate Past President



Dr. Madhuri Patel
Secretary General 2021



Dr. Hrishikesh D. Pai
President Elect



Dr. Jaydeep Tank
Secretary General 2020

REGISTER NOW



Vani
A step towards happiness

Dr. Kamini Patel
Awarded for "Best IVF Doctor"



OUR SERVICES

IVF Services

- TESA, PESA For Azoospermic Patients
- Special Team working for Reduced Ovarian Reserve
- Innovation for Implantation Failure
- IVF Specialist and well Trained Embryologist working with Aim of Using "Self Gametes"

Stem Cell Therapy

- Thin Endometrium
- Recurrent Implantation Failure
- Azoospermia

Surrogacy

Genetic Counselling by Geneticist

High End Laparoscopic Surgeries

High Risk Pregnancy

Ovarian Tissue Cryopreservation

Oocyte preservation

Vani IVF Centre
Now Consulting at...

- CIMS
- Morbi
- Lunawada
- Dakor
- Modasa
- Vadodra

Call Today and Start your Journey Towards Parenthood
☎ +91 9374747479 || 079 22721572

Like us :

TEAM



Vani Patel



Viren Patel



Dr. P.C. Shah



Vishal Pandhade



Dr. Jay Vaishnav



Dr. Kamal Parikh



Dr. Vinod Joshi



Dr. Kuntal Patel



Dr. Parth Patel

Management Team & Nursing Staff



25 - Asmita Society Nr. Kashivishvanath Temple, Maninagar(E), Ahmedabad, 380008